The Q1 miss may pressure the stock near-term, but focus should shift to upcoming PDUFA decisions and GTX-102 Phase 3 readout. Traders should weigh the weak quarter against pipeline catalysts; a beat on any of these could reverse sentiment.
Price Chart
Executive Summary
Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46), both missing expectations. Despite reaffirming full-year 2026 guidance of $730M-$760M revenue, the weak quarter and wider operating loss of $305M signal near-term headwinds, though upcoming PDUFA dates for DTX401 and UX111 provide potential catalysts.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $136M, down 2.2% YoY from $139M, missing consensus $158.4M
- Q1 2026 EPS -$1.84 vs consensus -$1.46; net loss $185M vs $151M YoY
- Reaffirmed full-year 2026 revenue guidance $730M-$760M and expense guidance
- R&D expenses $187M, up from $166M YoY; SG&A $88M flat
- Total operating expenses $305M included $30M restructuring and $30M stock-based compensation
- Cash and securities $534M; net cash used in operations $197M
- Two BLAs under FDA review with PDUFA dates: DTX401 (Aug 23, 2026) and UX111 (Sep 19, 2026)
- Phase 3 GTX-102 Angelman data expected H2 2026
Financial Impact
Revenue miss of ~$22M (14%) vs consensus; EPS miss of -$0.38 (26%) vs consensus
Risk Factors
- FDA delays or rejections for DTX401 or UX111
- Competition in Angelman syndrome and gene therapy
- Continued cash burn and need for additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288196 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $14.85 $15.22 | ▼ −2.49% | ▼ −3.68% | $15.22 (−2.49%) |
Sep 1, 2026 4w ago | Press Release | $26.53 $15.03 | ▼ −43.35% | ▼ −43.02% | $15.22 (−42.63%) |
Aug 11, 2026 7w ago | 8-K | $26.80 $14.31 | ▼ −46.60% | ▼ −45.55% | $15.22 (−43.21%) |
Aug 4, 2026 8w ago | 8-K | $24.93 $26.53 | ▲ +6.42% | ▲ +7.02% | $15.22 (−38.95%) |
Aug 4, 2026 8w ago | Insider Cluster | $25.81 $25.81 | · 0.00% | ▲ +1.24% | $15.22 (−41.03%) |
Jun 15, 2026 15w ago | Insider Cluster | $24.85 $32.03 | ▲ +28.89% | ▲ +28.69% | $15.22 (−38.75%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.98 $34.61 | ▲ +44.33% | ▲ +42.44% | $15.22 (−36.53%) |
May 5, 2026 21w ago | Press Release | $25.93 $22.41 | ▲ +13.57% | ▲ +16.36% | $15.22 (+41.30%) |
May 1, 2026 22w ago | Insider Cluster | $24.77 $22.85 | ▼ −7.75% | ▼ −13.04% | $15.22 (−38.55%) |
Apr 2, 2026 26w ago | 8-K | $22.45 $24.69 | ▲ +9.98% | ▲ +0.10% | $15.22 (−32.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access